Skip to main content
Top
Published in: Medical Oncology 4/2011

01-12-2011 | Original Paper

Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma

Authors: Bi Cheng Zhang, Juan Gao, Jun Wang, Zhi Guo Rao, Bao Cheng Wang, Jian Fei Gao

Published in: Medical Oncology | Issue 4/2011

Login to get access

Abstract

Tumor-associated macrophages (TAMs) have been implicated in promoting tumor progression. Nowadays, adenocarcinoma has surpassed squamous cell carcinoma as the most frequent type of lung cancer, but in lung adenocarcinoma, the correlation of TAMs with lymphangiogenesis patients remains unclear. The aim of this study was to examine the relationship between TAMs and lymphangiogenesis and the lung adenocarcinoma patients’ prognosis. Tumor specimens from 65 patients with lung adenocarcinoma were determined for TAMs count and lymphatic microvessel density (LMVD) by immunohistochemistry. A positive correlation existed between TAMs count and D2-40-positive peritumoral LMVD (r = 0.069, P < 0.001). TAMs infiltration was significantly associated with P-TNM staging (P = 0.042) and lymph node metastasis (P = 0.037), and peritumoral LMVD was correlated with lymph node metastasis (P = 0.003). A significant difference in overall survival was detected not only between tumors with a high TAMs count and a low TAMs count (P = 0.009) but also between tumors with a high peritumoral LMVD and a low peritumoral LMVD (P = 0.005). Both TAMs count and peritumoral LMVD were independent prognostic factors for overall survival. Our results indicate that TAMs infiltration correlates with tumor lymphangiogenesis and poor survival in lung adenocarcinoma.
Literature
1.
go back to reference Tiseo M, Bartolotti M, Gelsomino F, Ardizzoni A. First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype. Expert Rev Anticancer Ther. 2009;9:425–35.PubMedCrossRef Tiseo M, Bartolotti M, Gelsomino F, Ardizzoni A. First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype. Expert Rev Anticancer Ther. 2009;9:425–35.PubMedCrossRef
2.
go back to reference de Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol. 2006;13:118–37.PubMedCrossRef de Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol. 2006;13:118–37.PubMedCrossRef
3.
go back to reference Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86:1065–73.PubMedCrossRef Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86:1065–73.PubMedCrossRef
4.
go back to reference Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66:605–12.PubMedCrossRef Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66:605–12.PubMedCrossRef
5.
go back to reference Porta C, Subhra Kumar B, Larghi P, Rubino L, Mancino A, et al. Tumor promotion by tumor-associated macrophages. Adv Exp Med Biol. 2007;604:67–86.PubMedCrossRef Porta C, Subhra Kumar B, Larghi P, Rubino L, Mancino A, et al. Tumor promotion by tumor-associated macrophages. Adv Exp Med Biol. 2007;604:67–86.PubMedCrossRef
6.
go back to reference Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. 2008;66:1–9.PubMedCrossRef Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. 2008;66:1–9.PubMedCrossRef
7.
go back to reference Mantovani A. La mala educación of tumor-associated macrophages: diverse pathways and new players. Cancer Cell. 2010;17:111–2.PubMedCrossRef Mantovani A. La mala educación of tumor-associated macrophages: diverse pathways and new players. Cancer Cell. 2010;17:111–2.PubMedCrossRef
8.
go back to reference Takanami I, Takeuchi K, Kodaira S. Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology. 1999;57:138–42.PubMedCrossRef Takanami I, Takeuchi K, Kodaira S. Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology. 1999;57:138–42.PubMedCrossRef
9.
go back to reference Shieh YS, Hung YJ, Hsieh CB, Chen JS, Chou KC, et al. Tumor-associated macrophage correlated with angiogenesis and progression of mucoepidermoid carcinoma of salivary glands. Ann Surg Oncol. 2009;16:751–60.PubMedCrossRef Shieh YS, Hung YJ, Hsieh CB, Chen JS, Chou KC, et al. Tumor-associated macrophage correlated with angiogenesis and progression of mucoepidermoid carcinoma of salivary glands. Ann Surg Oncol. 2009;16:751–60.PubMedCrossRef
10.
go back to reference Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008;15:1069–74.PubMedCrossRef Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008;15:1069–74.PubMedCrossRef
11.
go back to reference Lee CH, Espinosa I, Vrijaldenhoven S, Subramanian S, Montgomery KD, et al. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res. 2008;14:1423–30.PubMedCrossRef Lee CH, Espinosa I, Vrijaldenhoven S, Subramanian S, Montgomery KD, et al. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res. 2008;14:1423–30.PubMedCrossRef
12.
go back to reference Stacker SA, Farnsworth RH, Karnezis T, Shayan R, Smith DP, et al. Molecular pathways for lymphangiogenesis and their role in human disease. Novartis Found Symp. 2007;281:38–43.PubMedCrossRef Stacker SA, Farnsworth RH, Karnezis T, Shayan R, Smith DP, et al. Molecular pathways for lymphangiogenesis and their role in human disease. Novartis Found Symp. 2007;281:38–43.PubMedCrossRef
13.
go back to reference Kim HS, Sung W, Lee S, Chang SG, Park YK. Lymphatic vessel densities of lymph node-negative prostate adenocarcinoma in Korea. Pathol Res Pract. 2009;205:249–54.PubMedCrossRef Kim HS, Sung W, Lee S, Chang SG, Park YK. Lymphatic vessel densities of lymph node-negative prostate adenocarcinoma in Korea. Pathol Res Pract. 2009;205:249–54.PubMedCrossRef
14.
go back to reference Schoppmann SF, Birner P, Stöckl J, Kalt R, Ullrich R, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol. 2002;161:947–56.PubMedCrossRef Schoppmann SF, Birner P, Stöckl J, Kalt R, Ullrich R, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol. 2002;161:947–56.PubMedCrossRef
15.
go back to reference Schoppmann SF, Fenzl A, Nagy K, Unger S, Bayer G, et al. VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery. 2006;139:839–46.PubMedCrossRef Schoppmann SF, Fenzl A, Nagy K, Unger S, Bayer G, et al. VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery. 2006;139:839–46.PubMedCrossRef
16.
go back to reference Zhang B, Wang J, Gao J, Guo Y, Chen X, et al. Alternatively activated RAW264.7 macrophages enhance tumor lymphangiogenesis in mouse lung adenocarcinoma. J Cell Biochem. 2009;107:134–43.PubMedCrossRef Zhang B, Wang J, Gao J, Guo Y, Chen X, et al. Alternatively activated RAW264.7 macrophages enhance tumor lymphangiogenesis in mouse lung adenocarcinoma. J Cell Biochem. 2009;107:134–43.PubMedCrossRef
17.
go back to reference Deniz H, Kibar Y, Güldür ME, Bakir K. Is D2–40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations? Pathol Res Pract. 2009;205:749–52.PubMedCrossRef Deniz H, Kibar Y, Güldür ME, Bakir K. Is D2–40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations? Pathol Res Pract. 2009;205:749–52.PubMedCrossRef
18.
go back to reference Pepper MS. Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res. 2001;7:462–8.PubMed Pepper MS. Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res. 2001;7:462–8.PubMed
19.
go back to reference Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001;20:672–82.PubMedCrossRef Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001;20:672–82.PubMedCrossRef
20.
go back to reference Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, et al. Vascular endothelial growth factor-D promotes the metastatic spread of cancer via the lymphatics. Nature Med. 2001;7:186–91.PubMedCrossRef Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, et al. Vascular endothelial growth factor-D promotes the metastatic spread of cancer via the lymphatics. Nature Med. 2001;7:186–91.PubMedCrossRef
21.
go back to reference Edwards JP, Zhang X, Frauwirth KA, Mosser DM. Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol. 2006;80:1298–307.PubMedCrossRef Edwards JP, Zhang X, Frauwirth KA, Mosser DM. Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol. 2006;80:1298–307.PubMedCrossRef
22.
go back to reference Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453–61.PubMedCrossRef Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453–61.PubMedCrossRef
23.
go back to reference Kojima H, Shijubo N, Yamada G, Ichimiya S, Abe S, et al. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer. 2005;104:1668–77.PubMedCrossRef Kojima H, Shijubo N, Yamada G, Ichimiya S, Abe S, et al. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer. 2005;104:1668–77.PubMedCrossRef
24.
go back to reference Renyi-Vamos F, Tovari J, Fillinger J, Timar J, Paku S, et al. Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res. 2005;11:7344–53.PubMedCrossRef Renyi-Vamos F, Tovari J, Fillinger J, Timar J, Paku S, et al. Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res. 2005;11:7344–53.PubMedCrossRef
25.
go back to reference Kadota K, Huang CL, Liu D, Ueno M, Kushida Y, et al. The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur J Cancer. 2008;44:1057–67.PubMedCrossRef Kadota K, Huang CL, Liu D, Ueno M, Kushida Y, et al. The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur J Cancer. 2008;44:1057–67.PubMedCrossRef
Metadata
Title
Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma
Authors
Bi Cheng Zhang
Juan Gao
Jun Wang
Zhi Guo Rao
Bao Cheng Wang
Jian Fei Gao
Publication date
01-12-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9638-5

Other articles of this Issue 4/2011

Medical Oncology 4/2011 Go to the issue